Dexamethasone and High-Dose Methotrexate in High-Risk B Cell Acute Lymphoblastic Leukemia—Where Should We Go From Here?
Journal of Clinical Oncology (JCO) Podcast · Hiroto Inaba
July 1, 201610m 32s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The Children's Oncology Group study led by Larsen et al. showed that children and young adult patients with high-risk B cell acute lymphoblastic leukemia benefit from receiving high-dose methotrexate during interim maintenance 1 and that those aged 1 to 9 years benefit from receiving dexamethasone for 14 days during induction.